Discovery MI Gen2

by GE HealthCare  · Based in United States → — Next generation. Even more in sight.
Nuclear Medicine Oncology Radiology

Contact vendor for pricing
Regulatory Status Disclosed

Overview

Discovery MI Gen2 is a cutting-edge hybrid digital PET/CT diagnostic imaging system developed by GE HealthCare. It integrates advanced Positron Emission Tomography (PET) and Computed Tomography (CT) technologies. The system features the LightBurst Digital Detector, offering a scalable axial field of view up to 30 cm and exceptionally high sensitivity. It incorporates TrueFidelity™, a deep-learning based image reconstruction technology, and Q.Clear quantitation for improved accuracy in SUV measurements and reduced image noise. Discovery MI Gen2 also includes MotionFree, a digital respiratory motion management solution, and Auto IN for automated patient positioning. These innovations aim to enhance small lesion detectability, reduce scan times and radiation dose, and provide a more efficient technologist and improved patient experience.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • LightBurst Digital Detector with scalable axial FOV up to 30 cm
  • High sensitivity (up to 125% increase, 30 cps/kBq)
  • TrueFidelityu2122 deep-learning based image reconstruction
  • Q.Clear quantitation for accurate SUV measurements and noise reduction
  • MotionFree digital respiratory motion management solution
  • Automated patient positioning system (Auto IN)
  • Reduced scan times (up to 50% reduction) and injected dose (up to 50% reduction)
  • Improved small lesion detectability (up to 41% increase)
  • Whole-body dynamic acquisition capabilities (WB Dynamic IQ Protocol)
  • Diagnostic CT innovations including Smart Metal Artifact Reduction (MAR)

Use Cases

  • Oncology: Detection, diagnosis, staging, restaging, and treatment response evaluation
  • Cardiology: Myocardial perfusion and function studies
  • Neurology: Diagnosis of Alzheimer's disease and other neurological pathologies
  • Theranostics treatment and monitoring
  • Research with novel, faster decaying tracers
  • Assessment of metabolic (molecular) and physiologic function

What Physicians Need to Know

Cardiac CT/MRI Analysis
The Discovery MI Gen2 integrates with Revolution EVO Gen 3 CT and utilizes TrueFidelity, a deep-learning-based image reconstruction technology, to deliver high-quality CT images with improved texture and reduced noise. This facilitates precise anatomical localization and enhances the diagnostic experience for cardiac conditions. It is used for myocardial perfusion and function studies, and the assessment of myocardial viability and perfusion. The system also supports stand-alone diagnostic CT imaging and is indicated for cardiovascular disease, myocardial perfusion, myocardial viability, cardiac inflammation, and coronary artery disease.
Coronary Artery Assessment
Leveraging its advanced diagnostic CT capabilities, including TrueFidelity deep-learning reconstruction, the Discovery MI Gen2 is relevant for detailed coronary artery assessment. Its indications for use include coronary artery disease.
Cardiac Monitoring Integration (Motion Correction)
The Discovery MI Gen2 features MotionFree, a fully digital respiratory motion management system. This AI-powered solution continually monitors respiratory motion during PET/CT procedures, automatically modifying the scan and integrating learned data into the final image in real-time, thereby eliminating the need for external gating devices and improving image clarity for cardiac scans.
Real-Time Alert Capability (MotionFree)
The MotionFree system detects respiratory motion anomalies and automatically modifies the scan in real-time, integrating corrections into the final image. This real-time adaptive capability ensures image quality and can be considered a form of real-time response to physiological changes during scanning.
AI-based Image Reconstruction & Quantification
The system incorporates TrueFidelity, a deep-learning-based image reconstruction technology for CT, providing high-quality images with improved texture and reduced noise. Additionally, the Q.Clear (BSREM) algorithm offers up to a twofold improvement in PET quantitation accuracy (SUVmean) and image quality (signal-to-noise ratio), crucial for precise diagnosis and treatment response assessment in cardiology.
Physician Tip

For cardiologists, the Discovery MI Gen2 offers advanced diagnostic capabilities through its integrated PET/CT system. Leverage the TrueFidelity deep-learning CT reconstruction for superior anatomical detail in coronary artery assessment and cardiac structural evaluation. Utilize the quantitative accuracy of Q.Clear for precise assessment of myocardial perfusion and viability, which is vital for guiding treatment strategies and monitoring disease progression. The MotionFree system is particularly beneficial for cardiac imaging, as it automatically corrects for respiratory motion, leading to clearer images and more reliable quantification without requiring patient cooperation with gating devices. Consider its utility for evaluating cardiac inflammation and other cardiovascular diseases where metabolic activity is a key indicator. The system's ability to perform whole-body dynamic acquisitions can provide deeper insights into tracer kinetics in cardiac tissues.

The Discovery MI Gen2 is a hybrid PET/CT system, integrating advanced digital PET technology with diagnostic CT capabilities, specifically the Revolution EVO Gen 3 CT. Its AI features, such as TrueFidelity and MotionFree, are built into the system's reconstruction and acquisition workflows. While direct integration with external ECG/EKG analysis or echocardiography platforms is not explicitly detailed as a native feature of the PET/CT scanner itself, the high-quality, quantitative imaging data it produces is intended to be complementary to other diagnostic modalities within a comprehensive cardiology workflow. Data generated by the system would typically be managed and reviewed within GE Healthcare's imaging workstations and PACS systems, allowing for integration into broader patient records.

Details

Category Cardiology AI, Neurology AI, Oncology AI
Pricing Contact vendor for pricing — Ultra-Premium tier (refurbished digital PET/CT systems): $950,000-$1,900,000
DeploymentOn-premise (physical hardware)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The GE Discovery MI Gen2 is a PET/CT system that received 510(k) clearance (K211846) on August 20, 2021. It is intended for producing attenuation-corrected PET images, imaging the distribution and localization of positron-emitting radiopharmaceuticals, and stand-alone diagnostic CT imaging.

Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

What the Web Says

The GE Healthcare Discovery MI Gen2 is an advanced digital PET/CT system designed to enhance diagnostic imaging in oncology, neurology, and cardiology. It features second-generation digital detectors, deep-learning based CT image reconstruction, and motion correction technology, aiming for higher resolution, increased sensitivity, and reduced scan times and radiation dose for patients. The system also focuses on improving the technologist's experience through efficient workflows.

Overall: Positive

Strengths

  • Higher diagnostic accuracy and detection of smaller lesions.
  • Up to 40% reduced radiation exposure for patients.
  • Faster examination process and increased patient comfort.
  • Exceptional system sensitivity, reaching up to 30 cps/kBq.
  • MotionFree technology for clear images by eliminating respiratory motion artifacts.
  • Deep-learning based CT image reconstruction (TrueFidelity) for enhanced image sharpness and improved noise texture.

Limitations

  • The 30 cm configuration is not yet available for sale in the U.S. due to pending FDA 510(k) approval.
  • No specific negative reviews from physicians, healthcare IT, or tech reviewers were found in the search results.
  • No reviews were found on Reddit, G2, or Capterra for this specific product.

Based on reviews from: GE HealthCare (Australia-New Zealand), GE HealthCare (Global English), GE HealthCare (Canada), GE Medical Systems, LLC (FDA 510(k) Premarket Notification), IASO Group, Radiology Today Magazine, GE HealthCare (United States), 1MDM

Last updated: 2026-07-17

Ratings & Reviews

Rate Discovery MI Gen2

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Beacon Hospital
New PET-CT Machine for Radiology - Beacon Hospital
Beacon Hospital in Ireland installed the new GE Discovery MI Gen2, a state-of-the-art fully digital PET-CT system, offering shorter scan times, lower radiation doses, and improved image quality for patients.
2023-02
PR Newswire
Subang Jaya Medical Centre Awarded Frost & Sullivan's Company of the Year Award for the Third Consecutive Year - PR Newswire
Subang Jaya Medical Centre (SJMC) in Malaysia is equipped with the new generation of the world's first digital PET/CT platform, Discovery MI Gen2, for optimal care from detecting disease to treatment planning and assessment.
2023-06
Citizens Journal
SJMC receives the 2023 Company of the Year Award - Citizens Journal
Subang Jaya Medical Centre (SJMC) has been honored with the 2023 Company of the Year Award by Frost & Sullivan, highlighting its use of advanced medical technologies like the Discovery MI Gen2 digital PET/CT platform for cancer care.
2023-06
Max Healthcare Institute Limited Annual Report 2022-23
Healthier communities. Sustainable future. - Cloudfront.net
Max Healthcare Institute Limited's 2022-23 annual report mentions the installation of a premium PET/CT, the GE Discovery MI Gen2, which offers clearer images with motion-free digital respiratory motion management and accurate quantitative measurement.
2023-03
FDA
Establishment Registration & Device Listing - accessdata.fda.gov
This FDA listing provides regulatory information for Discovery MI Gen2, classified as a Class II device under regulation number 892.1200 for a computed emission tomography system.
2026-07
FDA
Establishment Registration & Device Listing - accessdata.fda.gov
This FDA listing details the Discovery MI Gen2 as a Class II computed tomography X-ray system under regulation number 892.1750.
2026-03
PMC (PubMed Central)
Theranostics and artificial intelligence: new frontiers in personalized medicine - PMC
This peer-reviewed article discusses the role of AI in theranostics and lists Discovery MI Gen2 (K211846, 2021) as a PET/CT system for producing attenuation corrected images.
2025-12
PMC (PubMed Central)
Role of 18F-FDG-PET in renal tumors: insights from WHO 2022 classification - PMC
This peer-reviewed article on the role of 18F-FDG-PET in renal tumors mentions that cases presented were imaged using devices including the Discovery MI Gen2.
2025-04

Videos

Product demos, reviews, and walkthroughs for Discovery MI Gen2.

Loading videos...

View all on YouTube

Frequently Asked Questions

Discovery MI Gen2 incorporates deep-learning based image reconstruction, specifically TrueFidelity, to enhance image sharpness and reduce noise, providing a more classic image texture for radiologists. This AI integration, along with features like Q.Clear quantitation and MotionFree respiratory motion management, aims to improve small lesion detectability, reduce scan times, and optimize patient dose, ultimately leading to more confident diagnoses and a better patient experience.
Discovery MI Gen2 is designed and manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485, and has completed testing in compliance with IEC 60601-1 Ed. 3, 21CFR Subchapter J, and NEMA XR-25, XR-26, XR-28, and XR-29. It is FDA-cleared for imaging the distribution and localization of positron-emitting radiopharmaceuticals for metabolic and physiologic function assessment in patients of all ages, and for stand-alone diagnostic CT imaging.
Discovery MI Gen2 is primarily used in oncology for detection, diagnosis, staging, and treatment response evaluation, as well as in cardiology for myocardial perfusion and function studies, and in neurology for conditions like Alzheimer's disease. Its high sensitivity, scalable axial field of view up to 30 cm, and advanced quantitative software like Q.Clear contribute to improved small lesion detectability, reduced scan times, and lower radiation doses, enhancing diagnostic confidence and efficiency.
Key alternatives in the PET/CT market include Siemens Healthineers' Biograph Vision series and United Imaging's uEXPLORER. Discovery MI Gen2 differentiates itself with its 2nd generation LightBurst Digital Detector technology, offering exceptional sensitivity, a scalable 30 cm axial field of view, and deep-learning based CT image reconstruction (TrueFidelity) for enhanced image quality and workflow efficiency.
While AI features like TrueFidelity deep-learning reconstruction significantly improve image quality, physicians should be aware that processing software is needed for diagnostic purposes, and results can vary depending on clinical practice and circumstances. As with any advanced imaging system, proper training for technologists and physicians is crucial to maximize the benefits and accurately interpret the AI-enhanced images.
Specific pricing for a new Discovery MI Gen2 system is not publicly disclosed, but high-end PET/CT scanners like the Discovery MI generally fall into the range of $701,000+ for pre-owned models. Factors influencing the overall investment include the specific configuration (e.g., field of view, detector rings), included software packages, service agreements, installation requirements, and regional market variations.

Related Tools

4DMedical (Imbio)
4DMedical
Cardiology AI
4DMedical, with its acquisition of Imbio, offers a comprehensive suite of AI-driven medical imaging solutions for chronic lung and cardiothoracic diseases, providing quantitative and personalized insights from X-ray and CT scans.
Fetal EchoScan (v1.2)
BrightHeart (via AI Agent)
Cardiology AI
Fetal EchoScan (v1.2) is an AI-powered, FDA-cleared software designed to assist physicians in interpreting fetal heart ultrasound examinations for potential congenital heart defects.
Assert-IQ (DM5100)
Abbott (Assert-IQ ICM) / AI Agent (General AI Agent concept)
Cardiology AI
The Assert-IQ™ Insertable Cardiac Monitor (ICM) is a Bluetooth-enabled device from Abbott that provides continuous, real-time heart monitoring and arrhythmia detection, utilizing AI algorithms to reduce false positives and offer long-term diagnostic evaluation for patients with cardiac conditions.
QardioMD
Qardio
Cardiology AI
QardioMD offers an end-to-end virtual care platform with clinical-grade smart devices for remote patient monitoring of various chronic conditions, including hypertension and cardiovascular disease, and integrates with EHR systems.
PrepMD OMNI
PrepMD
Cardiology AI
PrepMD OMNI is an educational platform for cardiac rhythm management technology teams, focusing on training clinicians, hospitals, and practices in CRM device management.
Rapid Enterprise Platform
RapidAI
Cardiology AI
RapidAI's Enterprise Platform offers FDA-cleared, deep clinical AI solutions that connect imaging to clinical action across the health system, integrating with EHRs and PACS for enhanced decision-making and workflow efficiency.

See all Cardiology AI tools →

More from GE HealthCare

AI Orchestrator
GE HealthCare
Practice Management & Scheduling
GE HealthCare's AI Orchestrator integrates and manages AI applications within a healthcare imaging ecosystem to streamline workflows and improve diagnostic accuracy.
Aurora
GE HealthCare
Oncology AI
GE HealthCare's Aurora is an AI-powered dual-head SPECT/CT system designed to enhance diagnostic capabilities and streamline workflows in nuclear medicine, offering excellent image quality and operational efficiency for various clinical applications.
Centricity Universal Viewer
GE Healthcare
Radiology & Imaging AI
GE Healthcare's Centricity Universal Viewer is a web-based PACS with AI-powered tools, advanced visualization, and multi-modality support to enhance diagnostic confidence and streamline clinical workflows for radiologists and specialists.
Command Center
GE HealthCare
Practice Analytics & BI
GE HealthCare's Command Center is an AI-powered platform that optimizes hospital operations and patient flow through real-time visibility and predictive analytics.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.